Phase I Trial of Combination of FOLFIRI and SOM 230
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and
FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated
dose (MTD) of SOM 230 when combined with standard doses of FOLFIRI.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute